Basilea CEO Ronald Scott offered that the next best step for the biotech may be to just sell the Basel-based company to a U.S.-based biopharma company interested in a quick tax inversion deal that would allow a buyer the chance of trading American taxes for a sweeter deal in Switzerland.
Amid its fight to stave off a hostile takeover, Botox maker Allergan is making a buy of its own, trading up to $587.5 million for a midstage bladder drug from the biotech Taris.
InterMune's promising treatment for a rare lung disease has put it in Big Pharma's crosshairs, according to a report, news that sent the biotech's shares soaring as much as 20% on Wednesday.
Merck KGaA is talking up deals again, pointing to its healthy cash reserves and saying it can well afford a blockbuster buyout to bolster its pipeline. But that's been the story for nearly a year, so what's the German giant waiting on?
A top Valeant shareholder isn't saying the company can't win its hostile $53 billion takeover battle for Allergan. It's just saying it doesn't need to.
After making international headlines with the West's first approval for a gene therapy, pioneering biotech uniQure is working to flesh out its pipeline of one-time treatments, buying into an early-stage shot at heart failure that could put its technology on the biggest stage yet.
Dental company Nobel Biocare is reported to have attracted some suitors in its quest to sell itself, while speculation arises that healthcare analytics and management company CareFusion could be next up for a big M&A deal.
U.S. legislators are threatening to make it more difficult for American companies to take off for a new home in a tax-advantaged country. But what's in store for drugmakers who have already wrapped their own so-called tax inversion deals--and those who are planning them for the future?
Not only are we going to walk you through the top med tech M&A deals of the first half of 2014, but we will take a look back to how the acquisitions from the first half of 2013 are working out and if the acquirer got exactly what they bargained for.
CRO Venn Life Sciences is spreading its reach around Europe through M&A, buying up a French outsourcer to bolster its abilities in data management.